who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Vertex Pharmaceuticals (VRTX) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Nov 2

Net income

$654M

down 39.6% y/y

Total revenues

$3,441M

up 11.8% y/y

Income from operations

$713M

down 39.9% y/y

Next report

~ Feb 11

not announced yet

The quarter in brief

Vertex reported GAAP net income of $653.6 million ($2.56 per diluted share) on total revenues of $3,440.8 million for the third quarter of 2026, down from net income of $1,082.9 million ($4.20 per diluted share) on revenues of $3,076.4 million a year earlier.

Key growth driver: Revenue growth of +12% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report

All figures in $M.

Sankey diagram of VRTX (Vertex Pharmaceuticals) earnings report for Q3 2026: revenue, costs and profitTotal revenues$3,441 · +11.8%Cost of sales$526 · +26.8%Research anddevelopmentexpenses$1,321 · +35.1%Acquiredin-processresearch anddevelopmentexpenses$40.6 · −25.5%Selling, generalandadministrativeexpenses$844 · +89.6%Change in fairvalue ofcontingentconsideration$3.5 · +84.2%Income fromoperations$713 · −39.9%20.7% marginInterest income$118 · −5.8%Interest expense$36 · +991%Other (expense)income, net$11.9 · +21.4%Income beforeprovision forincome taxes$783 · −39.7%Provision for income taxes$130 · −39.9%16.6% effective rateNet income$654 · −39.6%$2.56/sh · 19.0% margin
Sankey diagram of VRTX (Vertex Pharmaceuticals) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Total revenues$3,441 · +11.8%
Cost of sales$526 · +26.8%
Research and development expenses$1,321 · +35.1%
Acquired in-process research and development expenses$40.6 · −25.5%
Selling, general and administrative expenses$844 · +89.6%
Change in fair value of contingent consideration$3.5 · +84.2%
Income from operations$713 · −39.9% · 20.7% margin
Interest income$118 · −5.8%
Interest expense$36 · +991%
Other (expense) income, net$11.9 · +21.4%
Income before provision for income taxes$783 · −39.7%
Provision for income taxes$130 · −39.9% · 16.6% effective rate
Net income$654 · −39.6% · $2.56/sh · 19.0% margin

Verdict: Vertex reported GAAP net income of $653.6 million ($2.56 per diluted share) on total revenues of $3,440.8 million for the third quarter of 2026, down from net income of $1,082.9 million ($4.20 per diluted share) on revenues of $3,076.4 million a year earlier.

Source and notation

Source: Vertex Pharmaceuticals earnings release, 8-K EX-99 of 11/02/2026 (SEC EDGAR).

Open as an image: Vertex Pharmaceuticals (VRTX), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Vertex Pharmaceuticals (VRTX) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/vrtx. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/vrtx"><img src="https://whoreportstoday.com/t/vrtx/img/vertex-pharmaceuticals-vrtx-earnings-sankey.png" alt="Vertex Pharmaceuticals (VRTX) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/vrtx">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/vrtx/img/vertex-pharmaceuticals-vrtx-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/vrtx">Vertex Pharmaceuticals (VRTX) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Vertex Pharmaceuticals — Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative treatments for serious diseases, particularly cystic fibrosis.

It is headquartered in Boston, Massachusetts.

Heads-up

Company reports

Q3 2026latest breakdownVertex reported GAAP net income of $653.6 million ($2.56 per diluted share) on total revenues of $3,440.8 million for…
Q2 2026A solid quarter with revenue up 12% led by ALYFTREK's rapid ramp and strong diversification (CASGEVY, JOURNAVX), but…

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $13.15–13.25Brevenue $12BEPS (GAAP) $15.32revenue +10%

Same quarter a year ago (ended December 31, 2025): revenue $3.19B, EPS (GAAP) $4.64

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +10%).

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Nov 2, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

VRTX earnings history: past report dates

Aug 3, 2026 Mon4:09 pmafter market closeJun 30, 2026$3.3B+12% y/y$4.31+8% y/y
May 4, 2026 Mon4:05 pmafter market closeMar 31, 2026$3.0B+8% y/y$4.02+61% y/y
Feb 12, 2026 Thu4:04 pmafter market closeDec 31, 2025≈$3.2B+10% y/y≈$4.64+28% y/y
Nov 3, 2025 Mon4:06 pmafter market closeSep 30, 2025$3.1B+11% y/y$4.20+5% y/y
Aug 4, 2025 Mon4:06 pmafter market closeJun 30, 2025$3.0B+12% y/y$3.99
May 5, 2025 Mon4:10 pmafter market closeMar 31, 2025$2.8B+3% y/y$2.49−41% y/y
Feb 10, 2025 Mon4:08 pmafter market closeDec 31, 2024≈$2.9B+16% y/y≈$3.62−2% y/y
Nov 4, 2024 Mon4:02 pmafter market closeSep 30, 2024$2.8B+12% y/y$4.01+1% y/y
Aug 1, 2024 Thu4:05 pmafter market closeJun 30, 2024$2.6B+6% y/y−$13.92
May 6, 2024 Mon4:03 pmafter market closeMar 31, 2024$2.7B+13% y/y$4.21+57% y/y
Feb 5, 2024 Mon4:09 pmafter market closeDec 31, 2023≈$2.5B+9% y/y≈$3.71+18% y/y
Nov 6, 2023 Mon4:05 pmafter market closeSep 30, 2023$2.5B+6% y/y$3.97+11% y/y
Aug 1, 2023 Tue4:03 pmafter market closeJun 30, 2023$2.5B+14% y/y$3.52+12% y/y
May 1, 2023 Mon4:08 pmafter market closeMar 31, 2023$2.4B+13% y/y$2.69−9% y/y
Feb 7, 2023 Tue4:07 pmafter market closeDec 31, 2022≈$2.3B+11% y/y≈$3.14+5% y/y
Oct 27, 2022 Thu4:06 pmafter market closeSep 30, 2022$2.3B+18% y/y$3.59+9% y/y
Show all 16 reports since 2022Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Vertex Pharmaceuticals: 15-year financials

202512,0014,1733,9533,194
202411,020−233−536−790
20239,8693,8323,6203,337
20228,9314,3073,3223,925
20217,5742,7822,3422,409
20206,2062,8562,7122,994
20194,1631,1981,1771,494
20183,0486352,0971,175
20172,489123264746
20161,7029.9−112180
20151,032−467−556−411
2014580−692−739−624
20131,212−610−445−112
20121,52746.7−107197
20111,41111429.6109

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Vertex Pharmaceuticals: 15-year balance sheet

YearAssetsEquityCashCurrent assetsCurrent liabilities
202525,64318,6665,08511,2013,861
202422,53316,4104,5709,5963,565
202322,73017,58010,36914,1443,547
202218,15113,91310,50413,2352,742
202113,43310,1006,7959,5612,142
202011,7528,6875,9888,1331,878
20198,3196,0853,1094,8231,335
20186,2464,4352,6503,8431,120
20173,5462,0291,6652,649807
20162,8971,1571,1841,832793
20152,4999407151,407506
20142,3351,0756251,547368
20132,3191,3565691,589398
20122,7599994891,590433
20112,2047874751,331392

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated3,1973,133+63.2
· incl. D&A (non-cash add-back)depreciation & amortization182154
· incl. stock-based comp (non-cash)share-based compensation511528
Capexpurchases of property & equipment−343−288−54.7
Free cash flow ≈operating cash flow − capex2,8542,845+8.5
Investing activities, netcapex, acquisitions, securities−6,578−657−5,921
· incl. acquisitionsbusinesses net of cash acquired−9,0630−9,063
Financing activities, netdebt, buybacks, dividends3,331−2,184+5,516
· incl. buybacksrepurchases of common stock−933−1,889+956
FX effect on cash−48.983.6−133
Net change in cash−99.2376−475
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $20.9B (64% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Feb 202610-K FY2025: apart from Note P, the company is not party to any material legal proceedings; no shareholder suits and no SEC cases. sec.gov ↗
  • Feb 2026Shares outstanding of 254.0M vs. 260.0M in January 2021 (−2.3%); SBC 5.7% of revenue. data.sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Apr 20262026 proxy: the only related-party transaction in 2025 was the COO/CFO's daughter, ~$155K. sec.gov ↗

Scoring: 2.0, no deductions: single share class, share count −2.3% over 5 years, SBC 5.7% of revenue (<10%), no dividends and no policy, no shareholder suits or SEC cases = 2.0

Share classes
Single class of common stock (Nasdaq: VRTX).
Dilution
Shares 260.0M (January 2021) → 254.0M (February 2026), −2.3%; SBC $686M = 5.7% of revenue (<10%); buybacks of $0.4–2.0B a year.
Disclosure
Full 10-K/10-Q reporting.
Dividends
No dividends and no payout policy.
Lawsuits & regulators
10-K: no material legal proceedings (other than those described in Note P); no shareholder suits and no SEC cases.
Related parties
2026 proxy: the only transaction is the COO/CFO's daughter in a non-executive role, ~$155K.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies with revenue growth 10 years in a row

Vertex Pharmaceuticals (VRTX) earnings: FAQ

When is VRTX's next earnings date?

We have not yet seen an announcement of the date from Vertex Pharmaceuticals (VRTX). Based on last year's report on Feb 12, 2026, the next report is expected around Feb 11, 2027.

What time does VRTX report earnings?

Vertex Pharmaceuticals usually reports after market close: its latest results release was filed with the SEC at 4:09 pm ET on Aug 3, 2026.

When did VRTX last report earnings?

Vertex Pharmaceuticals reported Q3 2026 results on Nov 2, 2026.

What has Vertex Pharmaceuticals guided for FY2026?

Company guidance for FY2026: revenue $13.15–13.25B. A year ago (FY2025): revenue $12B, EPS (GAAP) $15.32. Implied growth: revenue +10%. Source: the company's earnings release (Form 8-K filed Nov 2, 2026).

Where can I find Vertex Pharmaceuticals's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to VRTX's filings; this page breaks the latest report down in a Sankey chart.

What was VRTX's net income in Q3 2026?

Vertex Pharmaceuticals reported net income of $654M for Q3 2026 (−39.6% year over year), under US GAAP.

How has Vertex Pharmaceuticals's revenue changed since 2011?

Per its 10-K filings, revenue grew 8.5x: $1,411M in 2011 and $12,001M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: VTRS · Q2 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy